Trial Profile
DISTOL-1: Digital Ischaemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine: A Randomized, Double-blind, Placebo-controlled, Multicenter Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2021
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Systemic scleroderma
- Focus Therapeutic Use
- Acronyms DISTOL-1
- Sponsors United Therapeutics Corporation
- 15 Jun 2016 Results of a retrospective study from DISTOL-1 and DISTOL-EXT assessing digital ulcers burden after withdrawal from oral treprostinil (n = 51) published in The Journal of Rheumatology
- 25 Jun 2014 New trial record
- 22 Oct 2012